newsfilter
← Latest News
GlobeNewswire·

Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights

-New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022- -Results expected in Q2 from ongoing Phase 1 trial to inform dose selection for Phase 3- -$133 million in cash, cash